Text Size

Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients

This study has been completed.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00247429
First received: October 28, 2005
Last updated: August 31, 2009
Last verified: August 2009
History of Changes
  Purpose

In this study we will assess as a primary objective the effect of venlafaxine retard treatment on primary care attended elderly patients with depressive syndrome. We will also study secondarily its effects on anxiety, somatic and painful symptoms of depression.


Condition Phase
Depressive Syndrome
Anxiety
 Phase 4

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Vandral Retard (Venlafaxine Extended Release) in Depressive Syndrome With Anxiety and Painful Symptoms in Elderly Patients. Observational Study in Primary Care

Resource links provided by NLM:

MedlinePlus related topics: Anxiety Depression
U.S. FDA Resources

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Biospecimen Retention:   None Retained

No specimen retained


Enrollment: 59
Study Start Date: July 2004
Study Completion Date: October 2005
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Primary care centers

Criteria

Inclusion Criteria:

  • Patients older than 60 years
  • Depressive syndrome with associated anxiety symptoms, according to a symptoms intensity HAM-D17³14

Exclusion Criteria:

  • Participation in other studies in the last 3 months before the start of the study
  • Known hypersensibility to venlafaxine
  • Clinically significant abnormalities according to the venlafaxine labeling
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00247429

Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Principal Investigator: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00247429     History of Changes
Other Study ID Numbers: 101356
Study First Received: October 28, 2005
Last Updated: August 31, 2009
Health Authority: Spain: Ministry of Health

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
depression
anxiety
elderly

Additional relevant MeSH terms:
Anxiety Disorders
Depressive Disorder
Mental Disorders
Mood Disorders
Venlafaxine
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
 Pharmacologic Actions
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 16, 2013